Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
7:35AM NuPathe reports smaller-than-expected Q4 net loss (PATH) 4.50 : NuPathe reports Q4 EPS of ($0.38) vs ($0.49) Capital IQ Consensus Estimate; the co continues to believe it will be able to address all of the questions raised in the CRL for its migraine patch (NP101) in a timely fashion. NuPathe remains on track to resubmit its NDA in 1H12 and expects the resubmission will result in a six-month review by the Agency.
<<< $PATH Links! >>> ~ MAC's Quick DD Links without the charts.
PennyStockTweets ~ http://www.pennystocktweets.com/stocks/profile/PATH
OTC Markets Company Info ~ http://www.otcmarkets.com/stock/PATH/company-info
OTC Markets Charts ~ http://www.otcmarkets.com/stock/PATH/chart
OTC Markets Quote ~ http://www.otcmarkets.com/stock/PATH/quote
OTC Markets News ~ http://www.otcmarkets.com/stock/PATH/news
OTC Markets Financials ~ http://www.otcmarkets.com/stock/PATH/financials
OTC Markets Short Sales ~ http://www.otcmarkets.com/stock/PATH/short-sales
OTC Markets Insider Disclosure ~ http://www.otcmarkets.com/stock/PATH/insider-transactions
OTC Markets Research Reports ~ http://www.otcmarkets.com/stock/PATH/research
Google Finance Summary ~ http://www.google.com/finance?q=PATH
Google Finance News ~ http://www.google.com/finance/company_news?q=PATH
Google Finance Option chain ~ http://www.google.com/finance/option_chain?q=PATH
Google Finance Financials ~ http://www.google.com/finance?q=PATH&fstype=ii#
Google Finance Historical prices Daily ~ http://www.google.com/finance/historical?q=PATH
Google Finance Historical prices Weekly ~ http://www.google.com/finance/historical?q=PATH&histperiod=weekly#
Y! < Company >
Y! Profile ~ http://finance.yahoo.com/q/pr?s=PATH+Profile
Y! Key Stat's ~ http://finance.yahoo.com/q/ks?s=PATH+Key+Statistics
Y! Headlines ~ http://finance.yahoo.com/q/h?s=PATH+Headlines
Y! Summary ~ http://finance.yahoo.com/q?s=PATH
Y! Historical Prices ~ http://finance.yahoo.com/q/hp?s=PATH+Historical+Prices
Y! Order Book ~ http://finance.yahoo.com/q/ecn?s=PATH+Order+Book
Y! Message Boards ~ http://messages.finance.yahoo.com/mb/PATH
Y! Market Pulse ~ http://finance.yahoo.com/marketpulse/PATH
Y! Technical Analysis ~ http://finance.yahoo.com/q/ta?s=PATH+Basic+Tech.+Analysis
Y! < Analyst Coverage >
Y! Analyst Opinion ~ http://finance.yahoo.com/q/ao?s=PATH+Analyst+Opinion
Y! Analyst Estimates ~ http://finance.yahoo.com/q/ae?s=PATH+Analyst+Estimates
Y! Research Reports ~ http://finance.yahoo.com/q/rr?s=PATH+Research+Reports
Y! Star Analysts ~ http://finance.yahoo.com/q/sa?s=PATH+Star+Analysts
Y! < Ownership >
Y! Major Holders ~ http://finance.yahoo.com/q/mh?s=PATH+Major+Holders
Y! Insider Transactions ~ http://finance.yahoo.com/q/it?s=PATH+Insider+Transactions
Y! Insider Roster ~ http://finance.yahoo.com/q/ir?s=PATH+Insider+Roster
Y! < Financials >
Y! Income Statement ~ http://finance.yahoo.com/q/is?s=PATH+Income+Statement&annual
Y! Balance Sheet ~ http://finance.yahoo.com/q/bs?s=PATH+Balance+Sheet&annual
Y! Cash Flow ~ http://finance.yahoo.com/q/cf?s=PATH+Cash+Flow&annual
FINVIZ ~ http://finviz.com/quote.ashx?t=PATH&ty=c&ta=0&p=d
Investorshub Trades ~ http://ih.advfn.com/p.php?pid=trades&symbol=PATH
Investorshub Board Search ~ http://investorshub.advfn.com/boards/getboards.aspx?searchstr=PATH
Investorshub PostStream ~ http://investorshub.advfn.com/boards/poststream.aspx?ticker=PATH
Investorshub Messages ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=PATH
Investorshub Videos ~ http://ih.advfn.com/p.php?pid=ihvse&ihvqu=PATH
Investorshub News ~ http://ih.advfn.com/p.php?pid=news&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=PATH&s_ok=OK&from_month=3&from_day=15&from_year=2012&order=desc&selsrc%5B%5D=prnca&selsrc%5B%5D=prnus&selsrc%5B%5D=zacks&selsrc%5B%5D=money2&selsrc%5B%5D=djn&selsrc%5B%5D=bw&selsrc%5B%5D=globe&selsrc%5B%5D=edgar&selsrc%5B%5D=mwus&force=1&last_ts=1331855999&p_n=1&p_count=&p_ts=1331794260
CandlestickChart ~ http://www.candlestickchart.com/cgi/chart.cgi?symbol=PATH&exchange=US
Barchart Quote ~ http://barchart.com/quotes/stocks/PATH?
Barchart Detailed Quote ~ http://barchart.com/detailedquote/stocks/PATH
Barchart Options Quotes ~ http://barchart.com/options/stocks/PATH
Barchart Technical Chart ~ http://barchart.com/charts/stocks/PATH&style=technical
Barchart Interactive Chart ~ http://barchart.com/charts/stocks/PATH&style=interactive
Barchart Technical Analysis ~ http://barchart.com/technicals/stocks/PATH
Barchart Trader's Cheat Sheet ~ http://barchart.com/cheatsheet.php?sym=PATH
Barchart Barchart Opinion ~ http://barchart.com/opinions/stocks/PATH
Barchart Snapshot Opinion ~ http://barchart.com/snapopinion/stocks/PATH
Barchart News Headlines ~ http://barchart.com/news/stocks/PATH
Barchart Profile ~ http://barchart.com/profile//PATH
Barchart Key Statistics ~ http://barchart.com/profile.php?sym=PATH&view=key_statistics
OTC: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=PATH&MarketTicker=OTC&TYP=S
NASDAQ: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=PATH&MarketTicker=NASD&TYP=S
NYSE: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=PATH&MarketTicker=NYSE&Typ=S
Marketwatch Profile ~ http://www.marketwatch.com/investing/stock/PATH/profile
Marketwatch Analyst Estimates ~ http://www.marketwatch.com/investing/stock/PATH/analystestimates
Marketwatch Historical Quotes ~ http://www.marketwatch.com/investing/stock/PATH/historical
Marketwatch Financials ~ http://www.marketwatch.com/investing/stock/PATH/financials
Marketwatch Overview ~ http://www.marketwatch.com/investing/stock/PATH
Marketwatch SEC Filings ~ http://www.marketwatch.com/investing/stock/PATH/secfilings
Marketwatch Picks ~ http://www.marketwatch.com/investing/stock/PATH/picks
Marketwatch Hulbert ~ http://www.marketwatch.com/investing/stock/PATH/hulbert
Marketwatch Insider Actions ~ http://www.marketwatch.com/investing/stock/PATH/insideractions
Marketwatch Options ~ http://www.marketwatch.com/investing/stock/PATH/options
Marketwatch Charts ~ http://www.marketwatch.com/investing/stock/PATH/charts
Marketwatch News ~ http://bigcharts.marketwatch.com/news/symbolsearch/symbolnews.asp?news=markadv&symb=PATH&sid=1795093&framed=False
The Lion ~ http://thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&sa=1&fb=1&gg=1&symbol=PATH
Search NYSE ~ http://www.nyse.com/about/listed/lcddata.html?ticker=PATH
StockTA ~ http://www.stockta.com/cgi-bin/analysis.pl?symb=PATH&num1=567&cobrand=&mode=stock
StockHouse ~ http://www.stockhouse.com/financialtools/sn_overview.aspx?qm_symbol=PATH
StockHouse Delayed LII ~ http://www.stockhouse.com/financialtools/sn_level2.aspx?qm_page=46140&qm_symbol=PATH
AlphaTrade ~ http://tools.alphatrade.com/index.php?t1=mc_quote_module&t2=mc_quote_module2&t3=historical&template=historical2html&sym=PATH&client_id=2740&a_width=680&a_height=1000&language=english&showVol=1&chtype=8
Reuters ~ http://www.reuters.com/finance/stocks/companyOfficers?symbol=PATH.PK&WTmodLOC=C4-Officers-5
StockWatch ~ http://www.stockwatch.com/Quote/Detail.aspx?symbol=PATH®ion=U
Search NASDAQ ~ http://www.nasdaq.com/symbol/PATH
NASDAQ Divy History ~ http://www.nasdaq.com/symbol/PATH/dividend-history
NASDAQ Short Interest ~ http://www.nasdaq.com/symbol/PATH/short-interest
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/PATH/institutional-holdings
NASDAQ FlashQuotes ~ http://www.nasdaq.com/aspx/flashquotes.aspx?symbol=PATH&selected=PATH
NASDAQ InfoQuotes ~ http://www.nasdaq.com/aspx/infoquotes.aspx?symbol=PATH&selected=PATH
NASDAQ After Hours Quote ~ http://www.nasdaq.com/symbol/PATH/after-hours
NASDAQ Pre-Market Quote ~ http://www.nasdaq.com/symbol/PATH/premarket
NASDAQ Historical Quote ~ http://www.nasdaq.com/symbol/PATH/historical
NASDAQ Option Chain ~ http://www.nasdaq.com/symbol/PATH/option-chain
NASDAQ Company Headlines ~ http://www.nasdaq.com/symbol/PATH/news-headlines
NASDAQ Press Releases ~ http://www.nasdaq.com/symbol/PATH/news-headlines
NASDAQ Sentiment ~ http://www.nasdaq.com/symbol/PATH/sentiment
NASDAQ Analyst Summary ~ http://www.nasdaq.com/symbol/PATH/analyst-research
NASDAQ Guru Analysis~ http://www.nasdaq.com/symbol/PATH/guru-analysis
NASDAQ Stock Report ~ http://www.nasdaq.com/symbol/PATH/stock-report
NASDAQ Competitors ~ http://www.nasdaq.com/symbol/PATH/competitors
NASDAQ Stock Consultant ~ http://www.nasdaq.com/symbol/PATH/stock-consultant
NASDAQ Stock Comparison ~ http://www.nasdaq.com/symbol/PATH/stock-comparison
NASDAQ Call Transcripts ~ http://www.nasdaq.com/symbol/PATH/call-transcripts
NASDAQ Annual Reports ~ http://www.nasdaq.com/aspx/annualreport.aspx?symbol=PATH&selected=PATH
NASDAQ Financials ~ http://www.nasdaq.com/symbol/PATH/financials
NASDAQ Revenue & Earnings Per Share (EPS) ~ http://www.nasdaq.com/symbol/PATH/revenue-eps
NASDAQ SEC Filings ~ http://www.nasdaq.com/symbol/PATH/sec-filings
NASDAQ Ownership Summary ~ http://www.nasdaq.com/symbol/PATH/ownership-summary
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/PATH/institutional-holdings
NASDAQ (SEC Form 4) ~
--------- All Trades ~ http://www.nasdaq.com/symbol/PATH/insider-trades
--------- Buys ~ http://www.nasdaq.com/symbol/PATH/insider-trades/buys
--------- Sells ~ http://www.nasdaq.com/symbol/PATH/insider-trades/sells
The Motley Fool ~ http://caps.fool.com/Ticker/PATH.aspx
The Motley Fool Earnings/Growth ~ http://caps.fool.com/Ticker/PATH/EarningsGrowthRates.aspx?source=itxsittst0000001
The Motley Fool Ratios ~ http://caps.fool.com/Ticker/PATH/Ratios.aspx?source=itxsittst0000001
The Motley Fool Stats ~ http://caps.fool.com/Ticker/PATH/Stats.aspx?source=icasittab0000006
The Motley Fool Historical ~ http://caps.fool.com/Ticker/PATH/Historical.aspx?source=icasittab0000004
The Motley Fool Scorecard ~ http://caps.fool.com/Ticker/PATH/Scorecard.aspx?source=icasittab0000003
The Motley Fool Statements ~ http://caps.fool.com/Ticker/PATH/Statements.aspx?source=icasittab0000009
MSN Money ~ http://investing.money.msn.com/investments/stock-ratings?symbol=PATH
YCharts ~ http://ycharts.com/companies/PATH
YCharts Performance ~ http://ycharts.com/companies/PATH/performance
YCharts Dashboard ~ http://ycharts.com/companies/PATH/dashboard
InsideStocks Opinion ~ http://www.insidestocks.com/texpert.asp?sym=PATH&code=XDAILY
InsideStocks Profile ~ http://www.insidestocks.com/profile.asp?sym=PATH&code=XDAILY
InsideStocks Quote ~ http://www.insidestocks.com/quote.asp?sym=PATH&code=XDAILY
InsideStocks Projection ~ http://charts3.barchart.com/procal.asp?sym=PATH
Zacks Quote ~ http://www.zacks.com/stock/quote/PATH
Zacks Estimates ~ http://www.zacks.com/research/report.php?type=estimates&t=PATH
Zacks Company Reports ~ http://www.zacks.com/research/report.php?type=report&t=PATH
Knobias ~ http://knobias.10kwizard.com/files.php?sym=PATH
StockScores ~ http://www.stockscores.com/quickreport.asp?ticker=PATH
Trade-Ideas ~ http://www.trade-ideas.com/StockInfo/PATH/HOT_TOPIC.html
Morningstar ~ http://performance.morningstar.com/stock/performance-return.action?region=USA&t=PATH&culture=en-US
Morningstar Shareholders ~ http://investors.morningstar.com/ownership/shareholders-overview.html?t=PATH®ion=USA&culture=en-us
Morningstar Transcripts~ http://www.morningstar.com/earnings/NoTranscript.aspx?t=PATH®ion=USA
Morningstar Key Ratios ~ http://financials.morningstar.com/ratios/r.html?t=PATH®ion=USA&culture=en-US
Morningstar Executive Compensation ~ http://insiders.morningstar.com/trading/executive-compensation.action?t=PATH®ion=USA&culture=en-us
Morningstar Valuation ~ http://financials.morningstar.com/valuation/price-ratio.html?t=PATH®ion=USA&culture=en-us
CCBN (Thompson Reuters) ~ http://ccbn.aol.com/company.asp?client=aol&ticker=PATH
TradingMarkets ~ http://pr.tradingmarkets.com/?lid=leftPRbox&sym=PATH
OTCBB ~ http://www.otcbb.com/asp/SiteSearch.asp?Criteria=PATH&searcharea=e&image1.x=0&image1.y=0
Insidercow ~ http://www.insidercow.com/history/company.jsp?company=PATH&B1=Search%21
Forbes News ~ http://search.forbes.com/search/find?tab=searchtabgeneraldark&MT=PATH
Forbes Press Releases ~ http://search.forbes.com/search/find?&start=1&tab=searchtabgeneraldark&MT=PATH&pub=businesswire,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~ http://search.forbes.com/search/web?MT=UNGS&start=1&max=10&searchResults=web&tag=web&sort=null
YouTube Symbol Search ~ http://www.youtube.com/results?search_query=PATH
Buy-Ins ~ http://www.buyins.net/tools/symbol_stats.php?sym=PATH
Quotemedia ~ http://www.quotemedia.com/results.php?qm_page=47556&qm_symbol=PATH
Earnings Whispers ~ http://www.earningswhispers.com/stocks.asp?symbol=PATH
DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
IHUB DTCC BOARD SEARCH #1 http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=PATH
IHUB DTCC BOARD SEARCH #2: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=14482&srchyr=2011&SearchStr=PATH
Check those searches for recent PATH mentions. If PATH is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=Complete+list
For a complete list see the pinned threads at the top here ---> http://tinyurl.com/TWO-OLD-FARTS
MACDlinks
~ Tuesday! $PATH ~ Earnings posted, pending or coming soon! In Charts and Links Below!
~ $PATH ~ Earnings expected on Tuesday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.
http://stockcharts.com/h-sc/ui?s=PATH&p=D&b=3&g=0&id=p88783918276&a=237480049
http://stockcharts.com/h-sc/ui?s=PATH&p=W&b=3&g=0&id=p54550695994
~ Google Finance: http://www.google.com/finance?q=PATH
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=PATH#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=PATH+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=PATH
Finviz: http://finviz.com/quote.ashx?t=PATH
~ BusyStock: http://busystock.com/i.php?s=PATH&v=2
<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=PATH >>>>>>
http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916
*If the earnings date is in error please ignore error. I do my best.
If you look into Johnson and Johnson (IONSYS), they are also dedicating huge resources into the delvelopment of Iontophoresis technolgy. Iontophoresis technology is a clincally proven method of reducing pain and swelling in the ohysical therapy marketplace through Iontophoretic electrodes. This transdermal delivery will also be vertically integrating in many other areas for its clinical bnefits outway injections of many types of commonly delivered drugs...I agree PATH is definatley way under valued here....
NuPathe (PATH) is a company I am very impressed with, and I consider it one of the most undervalued companies I have ever seen, even after it made a nice run from $3.40 to $5.10 a share in just 3 trading sessions. As I remarked in my article about Nupathe, my short term target price was $4 a share, so I was also too low on that one. I honestly don't think my article is the main reason it moved so high, but more along the lines of investors not knowing about this little company with such a small market cap and the huge potential it has. Investors and traders just simply see what I see with Nupathe, as they should in my opinion.
Key pipelined drug: NP101
NP101 actively delivers sumatriptan, the most widely prescribed migraine medication. In clinical trials involving more than 10,000 applications, NP101 offered patients fast onset and sustained relief of debilitating migraine symptoms including headache pain and migraine-related nausea (MRN). It utilizes SmartRelief, a proprietary transdermal delivery technology that rapidly transports medication through the skin using a process called iontophoresis.
On Aug 30, 2011, NuPathe announced that it has received a Complete Response Letter (CRL) from the FDA regarding the New Drug Application (NDA) for its migraine patch (NP101 or Zelrix).
In the CRL, the FDA acknowledged that NuPathe established the efficacy of the migraine patch in the overall migraine population. The CRL primarily contained chemistry, manufacturing, and safety questions which the company believes it has, or shortly will have, sufficient data to address. The company may conduct additional clinical and/or non-clinical studies to address these issues.
The CRL is the only real reason the company's stock is not selling for at least 2 times its current price level of around $4.80 a share in my opinion. Efficacy was good, and I believe this is a viable and more efficient treatment for those who suffer from migraines that could be revolutionary in terms of bringing more effective relief and preventive recurrence of migraines. I believe the company has properly addressed the issues the FDA raised in the CRL response, so it is my opinion NP101 will be approved this time around.
The reason for my belief in this is because the company's management has years of experience dealing with The FDA, especially the company CEO. The data looks good in my opinion, and the CRL issues raised by the FDA are definitely fixable.
I hope to be doing a question and answer article with Nupathe CEO Jane H. Hollingsworth soon, so stay tuned for that.
http://seekingalpha.com/article/442351-a-review-of-my-last-3-small-cap-bio-pharma-picks?source=yahoo
NuPathe to Report Fourth Quarter and Full Year 2011 Results and Hold Conference Call on Tuesday, March 20, 2012
http://finance.yahoo.com/news/nupathe-report-fourth-quarter-full-123000731.html
NuPathe Pharma: A Possible Double On The Horizon
http://seekingalpha.com/article/433671-nupathe-pharma-a-possible-double-on-the-horizon?source=yahoo
7 Biotech Stocks Being Snapped Up By Insiders
http://seekingalpha.com/article/440021-7-biotech-stocks-being-snapped-up-by-insiders?source=yahoo
I really like this stock...5 dollaros in all silence lol
NuPathe to Report Fourth Quarter and Full Year 2011 Results and Hold Conference Call on Tuesday, March 20, 2012
Today : Tuesday 13 March 2012
NuPathe Inc. (NASDAQ: PATH), a biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, will report fourth quarter and full year 2011 results on Tuesday, March 20, 2012, before the open of the U.S. financial markets. NuPathe will also host a conference call at 8:30 a.m. EDT on the same day to discuss its fourth quarter and full year 2011 financial results and recent operational highlights. A question-and-answer session will follow NuPathe's remarks.
To participate on the live call, please dial 888-797-2982 (domestic) or +1-913-312-0380 (international), and provide the participant passcode 8797224 five to ten minutes before the start of the call. A replay of the call will be available for 90 days within a few hours after the call ends. Investors may listen to the replay of the call by dialing 888-203-1112 (domestic) or +1-719-457-0820 (international), with the passcode 8797224.
A live audio webcast of the call will be also available via the "Investor Relations" page of the NuPathe website, www.nupathe.com. Please log on through NuPathe's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on NuPathe's website for 90 days following the call.
About NuPathe
NuPathe Inc. is a biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. NuPathe is actively seeking partnerships to maximize the commercial potential for our pipeline products in the U.S. and territories throughout the world.
whats the deal? 6-30-12 Resubmit NDA for migraine patch 1H 2012
http://www.nupathe.com/nupathe-blog/innovating-neuroscience
http://ir.nupathe.com/
http://ih.advfn.com/p.php?pid=nmona&article=51508301
~ Monday! $PATH ~ Earnings posted, pending or coming soon! In Charts and Links Below!
~ $PATH ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.
http://stockcharts.com/h-sc/ui?s=PATH&p=D&b=3&g=0&id=p88783918276&a=237480049
http://stockcharts.com/h-sc/ui?s=PATH&p=W&b=3&g=0&id=p54550695994
~ Google Finance: http://www.google.com/finance?q=PATH
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=PATH#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=PATH+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=PATH
Finviz: http://finviz.com/quote.ashx?t=PATH
~ BusyStock: http://busystock.com/i.php?s=PATH&v=2
<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=PATH >>>>>>
http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916
*If the earnings date is in error please ignore error. I do my best.
Anyone know what the deal is with PATH? I cant find much info online... what are we waiting on? any important dates? LOWWW Volume seems common. Just looking for something to get excited in before I bail
4:21PM NuPathe announces allowance of U.S. patent application for NP202 (PATH) 3.01 +0.06 : Co announced that the United States Patent and Trademark Office has issued a notice of allowance for U.S. Patent application 11/183,232 entitled "Drug Containing Implants and Methods of Use Thereof." This application relates to a biodegradable polymer implant as well as novel methods of treating schizophrenia, bipolar disorder and other specified psychiatric disorders with the implant by delivering therapeutic levels of risperidone, 9-hydroxy-risperidone, or haloperidol for 20 to 190 days. Given this action, NuPathe expects the patent to issue within the next few months. Once issued, it will provide patent protection through January 2025 for NP202, NuPathe's long-term biodegradable risperidone implant for the treatment of schizophrenia and bipolar disorder. NuPathe has additional licensed patent applications pending in the U.S. and other territories for NP202.
Got in at 1.90. it.s going higher than 3.50. imo. volume increasing every week.
NuPathe to Present at Upcoming Investor Conferences
MarketwirePress Release: NuPathe Inc. – 19 hours ago
hopeful for continued rally into it
CONSHOHOCKEN, PA--(Marketwire -02/07/12)- NuPathe Inc. (NASDAQ: PATH - News), an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that Jane Hollingsworth, chief executive officer, will present company overviews at two upcoming investor conferences.
On Tuesday, February 14, 2012, NuPathe will present at the 14th Annual BIO CEO & Investor Conference at 3:00 p.m. EST. The conference is being held at The Waldorf Astoria Hotel in New York, NY.
On Wednesday, February 15, 2012, NuPathe will present at the Leerink Swann 2012 Global Healthcare Conference at 4:00 p.m. EST. The conference is also being held at The Waldorf Astoria Hotel in New York, NY.
Live audio webcasts of the presentations will be available via the "Investor Relations" page of the NuPathe website, www.nupathe.com. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. Replays of the webcasts will also be archived on NuPathe's website for 90 days following the presentation.
About NuPathe
NuPathe Inc. (www.nupathe.com) is an emerging biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.
Contact:
Contact Information:
John Woolford
Westwicke Partners, LLC
(443) 213-0506
john.woolford@westwicke.com
Keith A. Goldan
Vice President & Chief Financial Officer
NuPathe Inc.
(484) 567-0130
New press release about Patch :)
Our Company
Pipeline
Partnering
Investor Relations
Newsroom
NuPathe Blog
Migraine Resources
Careers
Contact Us
Overview
Press Releases
Events and Presentations
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
Information Request
Annual Reports & Proxy Statements
Investor FAQs
. .
NuPathe Announces Allowance of Additional U.S. Patent Application for Its Migraine Patch
CONSHOHOCKEN, PA--(Marketwire - Jan 19, 2012) - NuPathe Inc. (NASDAQ: PATH), an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that the United States Patent and Trademark Office has issued a notice of allowance for U.S. Patent application 12/142,604 entitled "Pharmacokinetics of Iontophoretic Sumatriptan Administration." This application relates to methods of treating a migraine by administering sumatriptan using an iontophoretic patch to achieve consistent therapeutic plasma levels with low patient-to-patient variability. Given this action, NuPathe expects the patent to issue within the next few months. Once issued, it will provide additional patent protection through April 2027 for NP101, NuPathe's lead product candidate for the treatment of migraine.
This coverage is in addition to that provided by NuPathe's U.S. Patent No. 7,973,058 entitled "Transdermal Methods and Systems for Delivery of Anti-Migraine Compounds," which expires in April 2027, and its U.S. Patent No. 6,745,071 entitled "Iontophoretic Drug Delivery System," which expires in February 2023. Upon approval of NuPathe's New Drug Application (NDA) for NP101, NuPathe expects to list all three patents in the U.S. Food & Drug Administration's (FDA's) Orange Book. NuPathe also has additional patent applications pending in the U.S. and other territories for its migraine patch.
"Issuance of this patent will further strengthen our intellectual property related to NP101," said Jane Hollingsworth, chief executive officer of NuPathe. "If approved, our breakthrough technology will offer the first-ever patch for migraine, providing rapid, consistent and controlled delivery through the skin of the most widely prescribed migraine medication. We look forward to re-submitting our NDA for the migraine patch in the first half of this year."
Nupathe's Zelrix Going Down A Path With Multiple Headwinds
http://seekingalpha.com/article/312885-nupathe-s-zelrix-going-down-a-path-with-multiple-headwinds?source=yahoo
PATH hod= $3.12 sweeet
Come on people! Filled 75% position last few weeks and was hoping to fill the other 25% in the 2.50 to 2.60 range does not look like that's going to happen. Might have to buy the rest at much higher price. Will have the rest by the 9th though.
gee, europe is bloodred. better wait for another hour to c how we r doin´ here!
sick market. think 2.63 is good enough to get in here!
on the right PATH ($2.56)
PATH new dynamics in november; keep it;
NuPathe (Nasdaq:PATH - News) is an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe’s lead product candidate, NP101 (also known as Zelrix), is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine, and is the first-ever submission to the U.S. Food and Drug Administration (FDA) of a transdermal patch for migraine treatment. The patch is designed to provide migraine patients fast onset and sustained relief of the cardinal migraine symptoms including headache pain and migraine-related nausea (MRN). On August 30, 2011, NuPathe announced receipt of a Complete Response Letter (CRL) from the FDA regarding the New Drug Application (NDA) for its migraine patch. "Following an end-of-review meeting with the FDA on November 9th to discuss the questions the FDA raised in its CRL, NuPathe expects to determine the timing of the resubmission of its NDA and the commercial launch of its migraine patch. In addition to NP101, NuPathe has two additional proprietary product candidates: NP201 for the continuous symptomatic treatment of Parkinson’s disease, for which the company plans to partner, and NP202, in preclinical development, for the long-term treatment of schizophrenia and bipolar disorder. NuPathe’s initial public offering of common stock in August 2010 raised $50 million in gross proceeds. Safeguard has deployed $18.3 million of capital in NuPathe since September 2006 and owns 18% of its outstanding common shares. "
NuPathe Reports Positive Top-Line Results From 12-Month, Repeat Use Safety Trial for Its Migraine Patch
Press Release Source: NuPathe Inc. On Monday October 3, 2011, 8:30 am EDT
CONSHOHOCKEN, PA--(Marketwire -10/03/11)- NuPathe Inc. (NASDAQ: PATH - News) today announced positive top-line results from NP101-009, its second 12-month, repeat use safety trial for its migraine patch (NP101 or Zelrix).
NP101-009 was designed to assess the long-term safety of the migraine patch. A total of 479 patients were enrolled and applied at least one patch. Consistent with the findings from previous studies, the incidence of adverse events known as triptan sensations, which can include chest tightness, flushing and feelings of pressure and numbness, was very low, with only four patients (0.8 percent) reporting a triptan sensation over the course of the 12-month trial.
"We now have treated more than 800 patients who applied greater than 10,000 patches in our Phase III clinical program," commented Mark Pierce, MD, Ph.D., chief scientific officer of NuPathe. "Our clinical data have consistently shown a very low rate -- 1.4 percent in fact -- of triptan sensations across patients who have used our patch to treat their migraine."
The most common adverse events in the NP101-009 study occurred at the patch application site and included: application site pain (18.6 percent of patients), application site itching (14.0 percent) and application site reaction (6.1 percent). During the 12-month trial, 13.4 percent of patients withdrew from the study due to adverse events, primarily related to the patch application site.
"Based on the extensive clinical data from our entire Phase III clinical program, we believe that our patch will provide a valuable new treatment option that is particularly well-suited for the millions of migraine patients who suffer from debilitating migraine-related nausea along with their headache pain," said Jane Hollingsworth, chief executive officer of NuPathe. "We plan to present detailed results from the NP101-009 trial at an upcoming scientific meeting."
On August 30, 2011, NuPathe announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for its migraine patch. The Company believes that the complete data set for NP101-009 will be supportive of the resubmission of its NDA to the FDA.
About the Migraine Patch (NP101 or Zelrix)
NP101 is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. The patch is designed to provide migraine patients fast onset and sustained relief of the cardinal migraine symptoms including headache pain, migraine-related nausea (MRN), and sensitivity to light and sound. The non-oral route of the migraine patch may provide an attractive treatment option for millions of migraine patients who delay or avoid treatment with oral medications because of MRN. The migraine patch provides a transdermal dose of sumatriptan, the most widely prescribed migraine medication, with low incidence of triptan sensations that can include chest tightness, flushing and feelings of pressure and numbness. In addition, studies have shown the gastrointestinal (GI) tract slows during a migraine attack. The migraine patch's delivery bypasses the GI tract, making it an appealing treatment option for many of these patients. The patch is powered by SmartRelief™, NuPathe's proprietary transdermal delivery technology. SmartRelief consists of a controlled delivery technology that rapidly transports medication through the skin using a process called iontophoresis.
About NuPathe
NuPathe Inc. (www.nupathe.com) is an emerging biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates: NP201 for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and NP202 in preclinical development for the long-term treatment of schizophrenia and bipolar disorder.
It is taking the long way home. LOL. I was thinking it would be back over $3 by now but with a red market I can wait it out.
all the negative news baked in from fda crl, not much downside. $1 gain seems reasonable.
I got in at $2.50 and plan to hold until $3.50 at the least. Nice open today.
the pricetarget they have on it is high. who knows if the company will ever get there? i dont... they came up today with the rating update when the stock was at its lows. my decision was to buy and share the information. bounce time.
PATH asked additional info: 2.06-2.66
FDA Requests Additional Information Regarding NuPathe's Migraine Patch in Complete Response Letter
Date : 08/30/2011 @ 6:30AM
Source : MarketWire
Stock : NuPathe Inc. (PATH)
Quote : 2.7008 -1.3482 (-33.30%) @ 12:34PM
FDA Requests Additional Information Regarding NuPathe's Migraine Patch in Complete Response Letter
print
Nupathe Inc. (MM) (NASDAQ:PATH)
Intraday Stock Chart
Today : Tuesday 30 August 2011
Click Here for more Nupathe Inc. (MM) Charts.
NuPathe Inc. (NASDAQ: PATH) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for its migraine patch (NP101 or Zelrix). A CRL is issued by the FDA's Center for Drug Evaluation and Research when the review of an NDA is completed and questions remain that preclude the FDA from approving the NDA at the time.
In the CRL, the Agency acknowledged that NuPathe established the efficacy of the migraine patch in the overall migraine population. The CRL primarily contained chemistry, manufacturing and safety questions, which the Company believes it has, or shortly will have, sufficient data to address. The Company may conduct additional Phase I and/or non-clinical studies to address other questions. NuPathe will request an End-of-Review meeting with the Agency to discuss the CRL and the Company's approach to resolving the outstanding issues. The issuance of this CRL means that the Company will not launch its migraine patch in the first half of 2012, as previously announced.
"This CRL gives us confidence that we can provide the information needed to support FDA approval for our migraine patch in a timely manner," said Jane Hollingsworth, CEO of NuPathe. "We continue to believe that our patch will address the symptoms of millions of patients who suffer from debilitating migraine headache pain and migraine-related nausea. We look forward to working with the FDA to bring this important product to market."
Give me $3+ eod~ and we have a deal here... Nice bounce so far PATH.
Got in this morning, "down there." Oversold, IMO! The "chain reaction" works most of the time & taking advantage of such opportunities is usually good.
Mike
I am going to try and hold until $3.50 ir better. I think we could see $3 before Noon at this pace
I put the case per share after funding execution at just under $4 per share. Why would they not execute the agreement. I am with you this will go over #3 per share within days and out for a quick buck.
I got in at $2.50 I think this will break $3 soon IMO.
Got in here at $2.50. Moving up fast.
Once the funding agreement is executed, the cash per share is over $2 per share. Since this is their platform technology, all the stops will be pulled out to obtain approval. Catch the wave up! I am out at $3.
Still $$$ to be made here. looking for more nibbles here!!!
PATH
NuPathe To Provide Additional Zelrix Data To FDA, Delays Launch ON going in my book...
6:54 AM ET 8/30/11 | Dow Jones
DOW JONES NEWSWIRES
NuPathe Inc. (PATH) said it has received a letter from the U.S. Food & Drug Administration raising chemistry, manufacturing and safety questions related to the company's new drug application for its Zelrix migraine patch.
The company said it believes it will have sufficient data to address the FDA's concerns and may conduct additional Phase I or non-clinical studies to address the questions. As a result, NuPathe said it won't launch Zelrix in the first half of 2012 as expected.
In October, NuPathe said a yearlong study showed Zelrix was shown to relieve migraine headache pain in a majority of incidences. The FDA's letter acknowledged NuPathe had established the efficacy of the patch in the overall migraine population.
The specialty pharmaceutical company, which went public last year, makes treatments for central nervous system disorders. Zelrix, NuPathe's most advanced drug candidate, would deliver sumatriptan--used currently in pills for the ailment--through the skin using a mild electrical current.
Shares closed at $4.05 Monday and were inactive premarket. The stock is off 48% in the past 12 months.
--By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com
> Dow Jones Newswires
08-30-11 0654ET
Copyright (c) 2011 Dow Jones & Company, Inc.
PATH $2.16s let's get to the bottom of this
I just lost a perfectly good set of Depends on this....clean up aisle 4
That is laughable..........I guess you had a reason for that post!
Wedbush pricetargets are based on approval, they never said hold thru it.
Wedbush was dead wrong on their call & PATH PPS will be bouncing around $2 for some time to come.
NuPathe PATH Wedbush Outperform $20
http://www.breifing.com/investor/calendars/upgrades-downgrades/
Followers
|
36
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
724
|
Created
|
10/07/10
|
Type
|
Free
|
Moderators |
Our first commercial product is Zecuity™ sumatriptan iontophoretic transdermal system (patch) for the acute treatment of migraine. We are seeking commercialization partners in the U.S. and worldwide.
In addition, we have a strong pipeline based on our biodegradable implant technology that allows us to deliver therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist and is being developed to provide up to two months of continuous delivery. NP202 is being developed to address patient noncompliance, a long-standing problem in the treatment of schizophrenia and bipolar disorder, by providing three months of continuous delivery of risperidone, an atypical antipsychotic. We are seeking a development partner for each of these candidates to capitalize on their commercial potential worldwide.
Beyond our current product pipeline, we intend to be a leader in the rapidly growing transdermal patch market with our active SmartRelief technology, delivering innovative solutions across a range of therapeutic areas.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |